Department of Medicine, University of California, San Francisco, CA 94143-0120, USA.
Lancet. 2011 Dec 3;378(9807):1949-61. doi: 10.1016/S0140-6736(11)60052-4. Epub 2011 Jun 28.
Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause that has few treatment options. This disease was once thought to be a chronic inflammatory process, but current evidence indicates that the fibrotic response is driven by abnormally activated alveolar epithelial cells (AECs). These cells produce mediators that induce the formation of fibroblast and myofibroblast foci through the proliferation of resident mesenchymal cells, attraction of circulating fibrocytes, and stimulation of the epithelial to mesenchymal transition. The fibroblast and myofibroblast foci secrete excessive amounts of extracellular matrix, mainly collagens, resulting in scarring and destruction of the lung architecture. The mechanisms that link idiopathic pulmonary fibrosis with ageing and aberrant epithelial activation are unknown; evidence suggests that the abnormal recapitulation of developmental pathways and epigenetic changes have a role. In this Seminar, we review recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis.
特发性肺纤维化是一种严重的、与年龄相关的肺部疾病,其病因不明,治疗选择有限。这种疾病曾经被认为是一种慢性炎症过程,但目前的证据表明,纤维化反应是由异常激活的肺泡上皮细胞(AECs)驱动的。这些细胞产生介质,通过募集循环成纤维细胞和刺激上皮细胞向间充质转化,诱导成纤维细胞和肌成纤维细胞灶的形成。成纤维细胞和肌成纤维细胞灶分泌大量细胞外基质,主要是胶原,导致肺组织结构的瘢痕形成和破坏。导致特发性肺纤维化与衰老和上皮细胞异常激活相关的机制尚不清楚;有证据表明,发育途径的异常重编程和表观遗传改变起了作用。在本次专题讨论会上,我们回顾了特发性肺纤维化发病机制中涉及的临床病程、治疗选择和潜在机制的最新数据。